First Quadrant L P CA cut its holdings in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 8.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,184 shares of the company’s stock after selling 1,875 shares during the quarter. First Quadrant L P CA owned approximately 0.08% of USANA Health Sciences worth $1,165,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in USANA Health Sciences by 10.6% in the second quarter. Renaissance Technologies LLC now owns 1,948,266 shares of the company’s stock worth $124,884,000 after acquiring an additional 186,600 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of USANA Health Sciences by 711.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 91,409 shares of the company’s stock valued at $5,859,000 after buying an additional 80,145 shares in the last quarter. FMR LLC increased its position in shares of USANA Health Sciences by 3.9% during the 2nd quarter. FMR LLC now owns 1,598,143 shares of the company’s stock valued at $102,441,000 after purchasing an additional 60,033 shares during the last quarter. Old Mutual Global Investors UK Ltd. increased its position in shares of USANA Health Sciences by 29.7% during the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 239,680 shares of the company’s stock valued at $15,363,000 after purchasing an additional 54,831 shares during the last quarter. Finally, Schroder Investment Management Group grew its position in USANA Health Sciences by 9.0% in the 2nd quarter. Schroder Investment Management Group now owns 572,186 shares of the company’s stock valued at $36,734,000 after acquiring an additional 47,448 shares during the last quarter. 44.54% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Global Ltd Gull sold 43,292 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $65.25, for a total transaction of $2,824,803.00. Following the transaction, the insider now directly owns 12,053,403 shares of the company’s stock, valued at $786,484,545.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider James Bramble sold 18,298 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $57.01, for a total transaction of $1,043,168.98. Following the transaction, the insider now directly owns 20,374 shares in the company, valued at $1,161,521.74. The disclosure for this sale can be found here. Insiders sold 542,489 shares of company stock worth $33,489,137 in the last three months. 53.20% of the stock is currently owned by corporate insiders.
USNA has been the subject of several research reports. BidaskClub cut USANA Health Sciences from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. Pivotal Research increased their price target on USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, October 25th.
Shares of USANA Health Sciences, Inc. (NYSE USNA) traded down $0.15 during trading on Monday, reaching $65.40. The company had a trading volume of 49,900 shares, compared to its average volume of 128,923. The stock has a market capitalization of $1,569.11, a P/E ratio of 17.30 and a beta of 1.07. USANA Health Sciences, Inc. has a 52-week low of $52.55 and a 52-week high of $71.00.
USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.11. USANA Health Sciences had a return on equity of 26.38% and a net margin of 8.79%. The business had revenue of $261.77 million for the quarter, compared to analysts’ expectations of $259.52 million. During the same quarter in the prior year, the firm posted $2.40 EPS. The company’s revenue was up 3.0% compared to the same quarter last year. research analysts forecast that USANA Health Sciences, Inc. will post 3.7 EPS for the current fiscal year.
USANA Health Sciences declared that its board has initiated a share buyback plan on Tuesday, July 25th that authorizes the company to buyback $64.60 million in outstanding shares. This buyback authorization authorizes the company to buy up to 46% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s leadership believes its shares are undervalued.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.